Diabetes

Androgens and Development of Posttransplantation Diabetes Mellitus in Male Kidney Transplant Recipients: A Post Hoc Analysis of a Prospective Study Suzanne P. Stam, Sara Sokooti, Michele F. Eisenga, Anna van der Veen, António W. Gomes-Neto, Peter R. van Dijk, Jelmer J. van Zanden, Michel J. Vos, Ido P. Kema, André P. van Beek, Stephan J.L.

Abstract OBJECTIVE Sulfonylureas, the first available drugs for the management of type 2 diabetes, remain widely prescribed today. However, there exists significant variability in glycemic response to treatment. We aimed to establish heritability of sulfonylurea response and identify genetic variants and interacting treatments associated with HbA1c reduction. RESEARCH DESIGN AND METHODS As an initiative of

Longitudinal Plasma Lipidome and Risk of Type 2 Diabetes in a Large Sample of American Indians With Normal Fasting Glucose: The Strong Heart Family Study Guanhong Miao, Ying Zhang, Zhiguang Huo, Wenjie Zeng, Jianhui Zhu, Jason G. Umans, Gert Wohlgemuth, Diego Pedrosa, Brian DeFelice, Shelley A. Cole, Amanda M. Fretts, Elisa T. Lee, Barbara V.

Abstract OBJECTIVE To investigate the occupational and financial consequences for parents following the onset of type 1 diabetes in their child. RESEARCH DESIGN AND METHODS A questionnaire assessing occupational and financial situations before and in the first year after the onset of diabetes was distributed to all families with a child ≤14 years of age

Abstract Certain chronic comorbidities, including diabetes, are highly prevalent in people with coronavirus disease 2019 (COVID-19) and are associated with an increased risk of severe COVID-19 and mortality. Mild glucose elevations are also common in COVID-19 patients and associated with worse outcomes even in people without diabetes. Several studies have recently reported new-onset diabetes associated

The prevalence of type 2 diabetes (T2D) has almost doubled since 1980 with targeted glycated hemoglobin (A1C) <7% being recommended to prevent complications (1). A recent study reported that 41% of a cohort of 35,304 patients with T2D from the U.S. and Sweden had suboptimal glycemic control (2). Therapeutic inertia, defined as “the failure to

The impact of obesity on health is reflected in different spheres and includes not only metabolic consequences, such as type 2 diabetes, but also psychological consequences related to obesity stigma. Studies show that almost 40% of adults with obesity are discriminated against because of their weight (1). Weight-based stereotypes may interfere with health care decision-making

Current guidelines strongly recommend regular, sharp debridement of diabetes-related foot ulcers (DFU) when blood flow is adequate (1). Sharp debridement disrupts biofilm and removes nonviable tissue, callus, and senescent cells, preparing the wound for endogenous healing (2) and advanced wound-healing therapies (3). Despite a reported association of more frequent debridement with improved healing outcomes (4),

Abstract Recent epidemiological data have shown that more than half of all new cases of type 1 diabetes occur in adults. Key genetic, immune, and metabolic differences exist between adult- and childhood-onset type 1 diabetes, many of which are not well understood. A substantial risk of misclassification of diabetes type can result. Notably, some adults

In a letter in this issue of Diabetes Care, Madias suggests that norepinephrine, as mediator of admission hyperglycemia (AH), is an index of increased underlying sympathetic overactivity and/or diabetes comorbidity in patients with takotsubo syndrome (TTS) (1). Indeed, the 28 patients with AH versus the 48 patients without AH had a higher prevalence of diabetes

I read with interest the contribution by Paolisso et al. (1) about the performance of admission hyperglycemia (AH) (blood glucose >140 mg/dL) as a predictor of long-term prognosis in 76 patients with takotsubo syndrome (TTS), 28 with and 48 without AH. Patients with AH showed lower left ventricular ejection fraction on admission and discharge and

We thank Lin et al. (1) for their interest in our article, which showed that abstainers from alcohol after diagnosis of type 2 diabetes had a lower risk of atrial fibrillation (AF) than the constant drinkers (2). Lin et al. suggested two issues with our article, namely, immortal time bias and drug-related confounding factors. Immortal

We read with great interest the article by Choi et al. (1), who investigated the impact of alcohol abstinence on the prevention of new-onset atrial fibrillation (AF) in patients with type 2 diabetes. They reported that alcohol abstinence was associated with a low risk of AF development in patients newly diagnosed with type 2 diabetes.

I thank Dr. Marathe and coauthors, who are part of the superb team of Michael Horowitz and Karen Jones, world-renowned top experts in gastric emptying (1), for recognizing the clinical value of our albiglutide switch study (HARMONY 8), which provided proof of concept for the benefits of using a weekly glucagon-like peptide 1 receptor agonist

We read with interest the study by Rosenstock et al. (1), which demonstrates that in patients with type 2 diabetes managed on a basal-bolus insulin regimen, switching three prandial insulin injections for a long-acting glucagon-like peptide 1 receptor agonist (GLP-1RA), albiglutide, while maintaining the basal insulin, represents an effective strategy for optimizing glycemic control with

ST-elevation myocardial infarction (STEMI) is one of the leading causes of death and hospitalization worldwide (1). Hyperglycemia (HG) has been shown to adversely affect STEMI clinical outcomes, leading to higher mortality and severe complications (1,2). The aim of our study was to investigate the impact of HG at hospital admission on the risk of restenosis

Hypoglycemia is an acute complication in people living with diabetes, with 83% of those with type 1 diabetes experiencing hypoglycemia at least once a month and even higher rates of 5 events per week recorded on continuous glucose monitoring (1). There are limited population-based data on the prevalence of impaired awareness of hypoglycemia (IAH) and

Hemoglobin A1c (HbA1c), microalbuminuria, and estimated glomerular filtration rate (eGFR) are widely used for assessment of diabetic kidney disease (DKD). However, we have shown that eGFR is inaccurate in DKD (1). Further, HbA1c has several limitations as a glycemic marker (2). Guidelines for hemodialysis patients in Japan recommend evaluation of glycemic control using glycated albumin

The Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) have given us fundamental insights into the natural history and management of diabetes (1,2). These include strong evidence that 1) enhanced glycemic management can limit some of the complications of diabetes, 2) there is a dose-response relationship between HbA1c levels and

Abstract Roger Pecoraro made important contributions to diabetic foot research and is primarily responsible for instilling in me an interest in these complications. Our collaboration in the final years of his life led to the development of the Seattle Diabetic Foot Study. At the time it began, the Seattle Diabetic Foot Study was perhaps unique

Abstract The discovery that HbA1c was a valid and reliable measure of average glucose exposure was one of the most important advances in diabetes care. HbA1c was rapidly adopted for monitoring glucose control and is now recommended for the diagnosis of diabetes. HbA1c has several advantages over glucose. Glucose assessment requires fasting, has poor preanalytic

The findings reported by Li et al. (1) in this issue of Diabetes Care are a welcome contribution to the body of evidence informing type 2 diabetes prevention. They focus on sedentary behavior (put simply, too much sitting), which has adverse health consequences that are distinct from those of too little exercise (2). These new